Trial Profile

Safety and Tolerability of Bevacizumab Plus Paclitaxel vs. Bevacizumab Plus Metronomic Cyclophosphamide and Capecitabine as First-Line Therapy in Patients With HER2-Negative Metastatic or Locally Recurrent Breast Cancer - A Multicenter, Randomized Phase III Trial

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Cyclophosphamide (Primary) ; Paclitaxel
Indications Adenocarcinoma; Advanced breast cancer
Focus Adverse reactions

07 May 2019 Status changed from active, no longer recruiting to completed.
14 Apr 2016 Planned End Date changed from 12 Feb 2016 to 1 Jun 2019.
07 Jan 2016 Planned End Date changed from 1 Oct 2015 to 12 Feb 2016 as reported by ClinicalTrials.gov record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com